Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ, Kozin SV, Matsui A, Goldberg SI, Aoki S, Shigeta K, Mamessier E, Smith MR, Michaelson MD, Lee RJ, Duda DG. Saylor PJ, et al. Among authors: duda dg. Radiother Oncol. 2024 Mar;192:110091. doi: 10.1016/j.radonc.2024.110091. Epub 2024 Jan 13. Radiother Oncol. 2024. PMID: 38224917
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models.
Morita S, Kikuchi H, Birch G, Matsui A, Morita A, Kobayashi T, Ruan Z, Huang P, Hernandez A, Coyne EM, Shin SM, Yarchoan M, Mino-Kenudson M, Romee R, Ho WJ, Duda DG. Morita S, et al. Among authors: duda dg. bioRxiv [Preprint]. 2023 Oct 23:2023.10.20.563378. doi: 10.1101/2023.10.20.563378. bioRxiv. 2023. PMID: 37961529 Free PMC article. Preprint.
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: duda dg. J Hepatocell Carcinoma. 2024 Mar 4;11:455-461. doi: 10.2147/JHC.S452564. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38463542 Free PMC article.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Dogra P, et al. Among authors: duda dg. Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5. Mol Cancer. 2024. PMID: 39095771 Free PMC article.
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Mohamed YI, et al. Among authors: duda dg. Cancer Biomark. 2024;41(1):83-91. doi: 10.3233/CBM-230431. Cancer Biomark. 2024. PMID: 39269823 Free PMC article.
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Johnston A, Olugbami JO, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK. Wu B, et al. Among authors: duda dg. ACS Pharmacol Transl Sci. 2024 Sep 5;7(10):3155-3169. doi: 10.1021/acsptsci.4c00358. eCollection 2024 Oct 11. ACS Pharmacol Transl Sci. 2024. PMID: 39416967
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade.
Tesfay MZ, Zhang Y, Ferdous KU, Taylor MA, Cios A, Shelton RS, Simoes CC, Watters CR, Barro O, Elliott NM, Mustafa B, Chamcheu JC, Graham AL, Washam CL, Alkam D, Gies A, Byrum SD, Giorgakis E, Post SR, Kelly T, Ying J, Moaven O, Chabu CY, Fernandez-Zapico ME, Duda DG, Roberts LR, Govindarajan R, Borad MJ, Cannon MJ, Basnakian AG, Nagalo BM. Tesfay MZ, et al. Among authors: duda dg. Mol Ther Oncol. 2024 Nov 26;32(4):200913. doi: 10.1016/j.omton.2024.200913. eCollection 2024 Dec 19. Mol Ther Oncol. 2024. PMID: 39758249 Free PMC article.
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: duda dg. J Immunother Precis Oncol. 2024 Nov 1;7(4):255-262. doi: 10.36401/JIPO-24-6. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524465 Free PMC article.
252 results